A Phase 2 interventional study of CEM-102 and Linezolid in Skin Diseases, Bacterial, sponsored by Arrevus Inc.. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-19.
Sponsored by Arrevus Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Skin Diseases, Bacterial with a site in United States — 1 open to participants now, 2 under way, 1 of them phase 3. Skin Diseases, Bacterial · United States.
Among the 22 studies in Skin Diseases, Bacterial with a site in United States, this one is the 13th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2009, is one of 9 in phase 2, and was the 9th registered.
37 studies on the registry are indexed under Skin Diseases, Bacterial; 2 are open to participants now.
Browse Skin Diseases, Bacterial studies →1 of the 22 studies in Skin Diseases, Bacterial with a site in United States is open now. Recruiting first, the newest first:
MoonLake Immunotherapeutics AG · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1 Skin Diseases, Bacterial study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2009.
This study's enrollment of 198 is below the median of 249 across 29 interventional studies indexed under Skin Diseases, Bacterial.
Median enrollment 234 across the 21 interventional studies. Of the 20 that completed or were terminated, 15 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 22 have an industry lead sponsor. The 10 most frequent:
Arrevus Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Arrevus Inc. has 1 study filed under Skin Diseases, Bacterial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Skin Diseases, Bacterial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and efficacy of CEM-102 compared to Linezolid in the treatment of acute bacterial skin structure infections (ABSSIs).
ABSSIs are common and affect all age groups. In recent years, ABSSIs caused by multi-drug resistant pathogens, especially methicillin-resistant Staphylococcus aureus (MRSA) have become more common. There is an urgent need for additional antibacterial drugs with modes of action different from those currently available. CEM-102 is one such agent with excellent activity against S. aureus, including MRSA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
600 mg BID
Drug: Linezolid
Drug: CEM-102
Drug: CEM-102
Clinical Success at Test of Cure (TOC) for the intent-to-treat (ITT) population
Meets the following definition for clinical success: continued complete resolution of the signs and symptoms of the ABSSI and no additional systemic antibacterial therapy is required
Time frame: 7 to 14 days after the last dose of study drug
Clinical Success at Test of Cure (TOC) for the clinically evaluable (CE) population
Meets the following definition for clinical success: continued complete resolution of the signs and symptoms of the ABSSI and no additional systemic antibacterial therapy is required
Time frame: 7 to 14 days after the last dose of study drug
Clinical Success at end of treatment (EOT) for the intent-to-treat (ITT) population
Meets the following definition for clinical success: Complete resolution of the signs and symptoms of the ABSSI and no further study drug therapy is required.
Time frame: 10-14 days of study drug
Clinical Success at the test of cure (TOC) in the microbiological intent-to-treat (MITT) and population
Meets the following definition for clinical success: Complete resolution of the signs and symptoms of the ABSSI and no additional systemic antibacterial therapy is required.
Time frame: 7 to 14 days after the last dose of study drug
Clinical Success at the end of treatment (EOT) for the Clinically evaluable (CE) population
Meets the following definition for clinical success: complete resolution of the signs and symptoms of the ABSSI and no further study drug therapy is required.
Time frame: 10-14 days of study drug
Clinical success at the end of treatment (EOT) for the microbiological intent-to-treat (MITT) population
Meets the following definition for clinical success at the end of treatment: complete resolutoin of the signs and symptoms of the ABSSI and no additional systemic antibacterial therapy is required
Time frame: 10-14 days of study drug
Clinical Success at end of treatment (EOT) for the microbiologically evaluable (ME) population
Meets the following definition for clinical success: complete resolution of signs and symptoms of the ABSSI and no additional systemic antibacterial therapy is required.
Time frame: 10-14 days of study drug
Clinical Success at test of cure (TOC) for the microbiologically evaluable (ME) population
Meets the following definition of clinical success: continued complete resolution of the signs and symptoms of the ABSSI and no additional systemic antibacterial therapy is required.
Time frame: 7-14 days after the last dose of study drug
Clinical success at the test of cure (TOC) by baseline pathogen for the microbiological intent-to-treat (MITT) population
Meets the following definition for clinical success: continued complete resolution of the signs and symptoms of the ABSSI and no additonal systemic antibacterial therapy is required
Time frame: 7-14 days after the last dose of study drug
Clinical success at test of cure (TOC) by baseline pathogen for the microbiologically evaluable (ME) population
Meets the following definition for clinical success: continued complete resolution of the signs and symptoms of the ABSSI and no additional systemic antibacterial therapy is required
Time frame: 7 to 14 days after the last dose of study drug
By-pathogen microbiological success at test of cure (TOC) for the microbiological intent-to-treat (MITT) population
Successful responses included: eradication: the basline causative pathogen was absent from the culture(s) presumed eradication: the patient's clincial response was success, and no culture available.
Time frame: 7-14 days after the last dose of study drug
By-pathogen microbiological success at test of cure (TOC) for the microbiologically evaluable (ME) population
Successful responses included: eradication: the basline causative pathogen was absent from the culture(s) presumed eradication: the patient's clincial response was success, and no culture available.
Time frame: 7-14 days after the last dose of study drug
By-patient microbiological success at test of cure (TOC) for the microbiological intent-to-treat (MITT) population
Successful responses included: eradication: the baseline causative organisms have a response of eradication. presumed eradication: all baseline causative organism(s) have a response of presumed eradication combined eradication/presumed eradication: in cases where baseline causative organisms were from a blood and an ABSSI culture
Time frame: 7-14 days after the last dose of study drug
By-patient microbiological success at test of cure (TOC) for the microbiologically evaluable (ME) population
Successful responses included: eradication: the baseline causative organisms have a response of eradication. presumed eradication: all baseline causative organism(s) have a response of presumed eradication combined eradication/presumed eradication: in cases where baseline causative organisms were from a blood and an ABSSI culture
Time frame: 7-14 days after the last dose of study drug
The record gives a start of Aug 2009, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fusidic Acid
Arrevus Inc.